Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - Garvey, WT; Frias, JP; Jastreboff, AM (Lancet, 2023)
et al.